BEOVU

Brolucizumab Treatment For Pigment Epithelial Detachment In Treatment-Resistant Neovascular Age Related Macular Degeneration

Study Type  : Observational
Estimated Enrollment  : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration
Actual Study Start Date  : November 5, 2020
Estimated Primary Completion Date  : November 7, 2024
Estimated Study Completion Date  : November 7, 2024

Related Publications

Our Affiliates